GlassScriptPhysician profile
Stacy Allison Meuth
NPI 1891871786
$9,207.43
in general payments reported to CMS, 2019-2025
33 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,235 · 2022: $1,751 · 2023: $1,884 · 2024: $2,332 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,186 · Education: $36.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,185.59 |
| Education | $36.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,794.72 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,672.38 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $737.72 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $448.19 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $414.12 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.21 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $336.33 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $312.12 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $311.24 | 2022-2025 | |
| Pfizer INC. | $196.94 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $150.85 | 2021-2024 | |
| Redhill Biopharma INC. | $146.50 | 2022-2024 | Talicia, Aemcolo, Movantik |
| Vivus LLC | $134.75 | 2025 | Pancreaze |
| Lilly USA, LLC | $128.11 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $123.14 | 2025 | Rezdiffra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $115.21 | 2021-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $88.25 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $83.08 | 2023-2025 | Ocaliva |
| Celltrion USA INC. | $76.38 | 2024-2025 | Vegzelma, Zymfentra |
| Shield Therapeutics INC | $59.23 | 2023 | Accrufer |
| Exact Sciences Corporation | $58.76 | 2023 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $57.77 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $51.65 | 2022-2023 | Sucraid |
| Genzyme Corporation | $51.19 | 2023-2024 | |
| Novo Nordisk INC | $48.49 | 2025 | Wegovy |
| Myriad Women'S Health, INC. | $37.64 | 2023 | Myrisk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.15 | 2023-2024 | Cyltezo |
| Echosens North America, INC. | $30.75 | 2025 | Fibroscan |
| Pentax of America, INC. | $30.33 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon |
| Alexion Pharmaceuticals, INC. | $22.66 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $22.04 | 2022 | |
| Evoke Pharma, INC. | $21.42 | 2025 | |
| Ferring Pharmaceuticals INC. | $17.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Meuth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.